EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The US FDA reportedly shelved and paused the commissioner's priority voucher pilot program for speedy drug reviews. The fast-track program was shuttered and ended amid reports of agency chaos, ahead of a Senate vote on Overton.
Epilogue added 2d ago, after coverage quieted.
The brief
The US Food and Drug Administration has shelved a priority review voucher pilot program championed by Commissioner Marty Makary, according to exclusive reporting from Reuters citing unnamed sources. The program, described as a flagship fast-track initiative, would have allowed drugmakers to receive expedited reviews for certain medications through a voucher system. The Independent characterizes the move as the FDA "quietly" shelving what it calls "Trump's flagship drug fast-track program" amid reports of agency chaos. TradingView notes the program was a "fast-track priority voucher pilot program." Pharmaphorum frames the question as whether "Makary's priority review vouchers" are "about to be canned." STAT includes the FDA shelving in its "Pharmalittle" roundup alongside other pharmaceutical industry news including a Canadian importer arrest.
The coverage emphasizes the program's association with Commissioner Makary and its status as a priority review voucher mechanism designed to accelerate drug approvals. Reuters' exclusive reporting cites sources saying the FDA has shelved the program, though the coverage does not specify the reasons cited by those sources or the exact timeline for the decision. The Independent's framing connects the shelving to broader reports of agency chaos, while pharmaphorum's headline poses the development as a question about the program's future. TradingView and STAT provide additional confirmation of the Reuters exclusive. None of the headlines specify which drugs or therapeutic areas would have been affected by the voucher program, nor do they detail the program's specific structure or eligibility criteria.
The coverage does not specify whether Makary's pilot program would have expanded existing voucher authorities or created a new framework. The Independent's reference to "Trump's flagship drug fast-track program" suggests a connection to the prior administration, though the coverage does not elaborate on the program's origins or whether it was formally proposed through rulemaking or operated as an internal pilot. The shelving comes amid what The Independent describes as reports of agency chaos, though the nature of those reports is not detailed in the headlines.
Based on the coverage, key developments to watch include whether the FDA issues an official statement confirming or clarifying the shelving, whether Commissioner Makary or other agency officials address the program's status publicly, and whether congressional oversight committees request information about the decision. The coverage does not indicate whether the program was formally announced before being shelved, whether any vouchers had been awarded or applications received, or whether the decision is reversible. Pharmaphorum's questioning headline suggests industry uncertainty about the program's definitive status. STAT's inclusion in a broader industry roundup indicates the development is being tracked alongside other regulatory and enforcement actions in the pharmaceutical sector.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated 5d ago.
Quick answers
What program has the FDA shelved?
The FDA has shelved a priority review voucher pilot program championed by Commissioner Marty Makary that would have allowed expedited drug reviews through a voucher system.
Which outlets reported this development?
Reuters published an exclusive report citing sources, with additional coverage from The Independent, TradingView, pharmaphorum, and STAT on November 12, 2026.
Why was the program shelved?
The coverage cites sources saying the program was shelved but does not specify the reasons. The Independent mentions reports of agency chaos as context.
Coverage (11)
- FDA’s speedy voucher program is dead: report Endpoints News · 5d ago
- Recon: FDA shelves commissioner's voucher program; Eli Lilly gets first GLP-1 weight-loss pill approved in China RAPS · 5d ago
- FDA appears to pause controversial speedy review program, complete response letter disclosures Fierce Pharma · 5d ago
- FDA’s Commissioner voucher program reportedly shuttered ahead of Senate vote on Overton BioSpace · 5d ago
- FDA Shelves Priority Voucher Pilot, Stalling Fast-Track Drug Reviews PharmTech.com · 5d ago
- US FDA shelves fast-track priority voucher pilot program: Reuters TradingView · 5d ago
- FDA quietly shelves Trump’s flagship drug fast-track program amid reports of agency chaos The Independent · 5d ago
- Are Makary's priority review vouchers about to be canned? pharmaphorum · 5d ago
- Pharmalittle: We're reading about FDA shelving fast-track review, a Canadian importer arrested, and more STAT · 5d ago
- EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say Reuters · 5d ago
- FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research The Microdose · 5d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'